跳至主要内容
临床试验/ISRCTN85533678
ISRCTN85533678进行中(未招募)未知

Pancreatic Cancer Testing in Emerging Diabetes (PACTED) using a urine 3-biomarker panel (LYVE1, REG1B, TFF1) and Serum CA 19-9

Spital Freiburg0 个研究点目标入组 1,000 人开始时间: 2018年10月1日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • Newly diagnosed diabetes mellitus, defined as HbA1c >6.5% (diagnosed within 1 month before inclusion)
  • Newly diagnosed prediabetes, defined as HbA1c > 6 % at two occasions with an interval of = 6 months (second measurement within the last month)
  • Participants should also have one or more of the following risk factors of PDAC:
  • 1. Aged 50 years or older
  • 2. Smoking
  • 3. Positive family history for PDAC
  • 4. Status post gestational diabetes
  • 5. Chronic pancreatitis

排除标准

  • 1. Inability to follow the procedures of the study or missing ability to provide informed consent (e.g. due to age, language, psychological factors, dementia, etc)
  • 2. Known PDAC
  • 3. Other preexisting gastrointestinal cancers
  • 4. Pregnancy
  • 5. Known severe renal insufficency (Clearance <30 ml)
  • 6. Aged below 18 years
  • Updated 28/05/2020:
  • 6. Aged below 40 years

研究者

发起方
Spital Freiburg

相似试验